(-)-epigallocatechin 3-gallate multiple interactions ISO RGD:1318046 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPS6KA5 mRNA CTD PMID:22079256 1,2-dimethylhydrazine decreases expression ISO RGD:1318047 6480464 1, 2-Dimethylhydrazine results in decreased expression of RPS6KA5 mRNA CTD PMID:22206623 17beta-estradiol multiple interactions ISO RGD:1318046 6480464 [Progesterone co-treated with Estradiol] results in decreased expression of RPS6KA5 mRNA CTD PMID:17404688 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1318047 6480464 Tetrachlorodibenzodioxin results in decreased expression of RPS6KA5 mRNA CTD PMID:19933214 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1318047 6480464 Tetrachlorodibenzodioxin promotes the reaction [RPS6KA5 protein binds to CYP1A1 enhancer] CTD PMID:24519526 3,3',5,5'-tetrabromobisphenol A decreases expression ISO RGD:1318047 6480464 tetrabromobisphenol A results in decreased expression of RPS6KA5 mRNA CTD PMID:25172293 3,4-methylenedioxymethamphetamine decreases expression ISO RGD:1318047 6480464 N-Methyl-3, 4-methylenedioxyamphetamine results in decreased expression of RPS6KA5 mRNA CTD PMID:26251327 3,4-methylenedioxymethamphetamine decreases methylation ISO RGD:1318047 6480464 N-Methyl-3, 4-methylenedioxyamphetamine results in decreased methylation of RPS6KA5 promoter CTD PMID:26251327 4,4'-diaminodiphenylmethane increases expression ISO RGD:1318047 6480464 4, 4'-diaminodiphenylmethane results in increased expression of RPS6KA5 mRNA CTD PMID:18648102 4-hydroxyphenyl retinamide decreases expression ISO RGD:1318047 6480464 Fenretinide results in decreased expression of RPS6KA5 mRNA CTD PMID:28973697 5-(1,4-diazepane-1-sulfonyl)isoquinoline decreases activity ISO RGD:1318046 6480464 fasudil results in decreased activity of RPS6KA5 protein CTD PMID:10998351 arsenite(3-) increases activity ISO RGD:1318047 6480464 arsenite results in increased activity of RPS6KA5 protein CTD PMID:11689710 benzo[a]pyrene decreases expression ISO RGD:1318047 6480464 Benzo(a)pyrene results in decreased expression of RPS6KA5 mRNA CTD PMID:22228805 benzo[a]pyrene affects methylation ISO RGD:1318046 6480464 Benzo(a)pyrene affects the methylation of RPS6KA5 3' UTR CTD PMID:27901495 benzo[a]pyrene multiple interactions EXP 6480464 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Benzo(a)pyrene promotes the reaction [TNF protein results in increased expression of RPS6KA5 protein modified form]], Benzo(a)pyrene promotes the reaction [TNF protein results in increased expression of RPS6KA5 protein modified form] CTD PMID:25233930 bis(2-chloroethyl) sulfide decreases expression ISO RGD:1318047 6480464 Mustard Gas results in decreased expression of RPS6KA5 mRNA CTD PMID:18955075 bis(2-chloroethyl) sulfide increases phosphorylation ISO RGD:1318047 6480464 Mustard Gas results in increased phosphorylation of RPS6KA5 protein CTD PMID:18200059 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of RPS6KA5 mRNA CTD PMID:25181051 , PMID:30816183 calcitriol decreases expression ISO RGD:1318046 6480464 Calcitriol results in decreased expression of RPS6KA5 mRNA CTD PMID:16002434 chloroprene increases expression EXP 6480464 Chloroprene results in increased expression of RPS6KA5 mRNA CTD PMID:23125180 cocaine increases expression EXP 6480464 Cocaine results in increased expression of RPS6KA5 mRNA, Cocaine results in increased expression of RPS6KA5 protein CTD PMID:17898221 , PMID:25100957 cocaine affects response to substance ISO RGD:1318047 6480464 RPS6KA5 affects the susceptibility to Cocaine CTD PMID:16339038 cocaine increases activity ISO RGD:1318047 6480464 Cocaine results in increased activity of RPS6KA5 protein CTD PMID:16339038 cocaine multiple interactions ISO RGD:1318047 6480464 Cocaine results in increased phosphorylation of and results in increased activity of RPS6KA5 protein, SL 327 inhibits the reaction [Cocaine results in increased phosphorylation of and results in increased activity of RPS6KA5 protein] CTD PMID:16339038 cyclosporin A increases expression ISO RGD:1318046 6480464 Cyclosporine results in increased expression of RPS6KA5 mRNA CTD PMID:20106945 deoxynivalenol increases phosphorylation ISO RGD:1318047 6480464 deoxynivalenol results in increased phosphorylation of RPS6KA5 protein CTD PMID:16424113 diclofenac decreases expression ISO RGD:1318047 6480464 Diclofenac results in decreased expression of RPS6KA5 mRNA CTD PMID:26934552 dorsomorphin multiple interactions ISO RGD:1318046 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPS6KA5 mRNA CTD PMID:27188386 doxorubicin decreases expression ISO RGD:1318046 6480464 Doxorubicin results in decreased expression of RPS6KA5 mRNA CTD PMID:29803840 endosulfan increases expression EXP 6480464 Endosulfan results in increased expression of RPS6KA5 mRNA CTD PMID:29391264 ethyl methanesulfonate increases expression ISO RGD:1318046 6480464 Ethyl Methanesulfonate results in increased expression of RPS6KA5 mRNA CTD PMID:23649840 fasudil hydrochloride decreases activity ISO RGD:1318046 6480464 fasudil results in decreased activity of RPS6KA5 protein CTD PMID:10998351 fenvalerate decreases expression EXP 6480464 fenvalerate results in decreased expression of RPS6KA5 mRNA CTD PMID:30307764 folic acid decreases expression ISO RGD:1318047 6480464 Folic Acid results in decreased expression of RPS6KA5 mRNA CTD PMID:25629700 formaldehyde increases expression ISO RGD:1318046 6480464 Formaldehyde results in increased expression of RPS6KA5 mRNA CTD PMID:23649840 gallic acid multiple interactions ISO RGD:1318046 6480464 Gallic Acid inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KA5 protein] CTD PMID:21420233 hexane decreases methylation EXP 6480464 n-hexane results in decreased methylation of RPS6KA5 promoter CTD PMID:23740543 hydralazine multiple interactions ISO RGD:1318046 6480464 [Hydralazine co-treated with Valproic Acid] results in increased expression of RPS6KA5 mRNA CTD PMID:17183730 hydrogen peroxide increases activity ISO RGD:1318047 6480464 Hydrogen Peroxide results in increased activity of RPS6KA5 protein CTD PMID:11689710 MeIQx increases expression ISO RGD:1318046 6480464 2-amino-3 more ... CTD PMID:20816883 metformin multiple interactions ISO RGD:1318046 6480464 [Metformin co-treated with Pioglitazone] results in decreased expression of RPS6KA5 mRNA CTD PMID:32589349 metformin decreases expression ISO RGD:1318046 6480464 Metformin results in decreased expression of RPS6KA5 mRNA CTD PMID:32589349 methyl methanesulfonate increases expression ISO RGD:1318046 6480464 Methyl Methanesulfonate results in increased expression of RPS6KA5 mRNA CTD PMID:23649840 mifepristone decreases expression EXP 6480464 Mifepristone results in decreased expression of RPS6KA5 mRNA CTD PMID:25972201 ML-7 decreases activity ISO RGD:1318046 6480464 ML 7 results in decreased activity of RPS6KA5 protein CTD PMID:12534346 N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide decreases activity ISO RGD:1318046 6480464 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of RPS6KA5 protein CTD PMID:10998351 , PMID:18377872 N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide decreases activity EXP 6480464 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of RPS6KA5 protein CTD PMID:15522277 nickel sulfate increases expression ISO RGD:1318046 6480464 nickel sulfate results in increased expression of RPS6KA5 mRNA CTD PMID:22714537 obeticholic acid decreases expression ISO RGD:1318046 6480464 obeticholic acid results in decreased expression of RPS6KA5 mRNA CTD PMID:27939613 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of RPS6KA5 mRNA CTD PMID:25729387 oxidopamine multiple interactions ISO RGD:1318047 6480464 [benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of RPS6KA5 protein more ... CTD PMID:17596448 , PMID:19187092 paraquat increases expression ISO RGD:1318047 6480464 Paraquat results in increased expression of RPS6KA5 mRNA CTD PMID:28012437 phenylephrine multiple interactions EXP 6480464 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of RPS6KA5 protein] more ... CTD PMID:15522277 , PMID:19002563 pioglitazone multiple interactions ISO RGD:1318046 6480464 [Metformin co-treated with Pioglitazone] results in decreased expression of RPS6KA5 mRNA CTD PMID:32589349 pirinixic acid multiple interactions ISO RGD:1318047 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of RPS6KA5 mRNA CTD PMID:19710929 potassium chromate multiple interactions ISO RGD:1318046 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of RPS6KA5 mRNA CTD PMID:22079256 potassium chromate decreases expression ISO RGD:1318046 6480464 potassium chromate(VI) results in decreased expression of RPS6KA5 mRNA CTD PMID:22079256 progesterone multiple interactions ISO RGD:1318046 6480464 [Progesterone co-treated with Estradiol] results in decreased expression of RPS6KA5 mRNA CTD PMID:17404688 quercetin increases phosphorylation ISO RGD:1318046 6480464 Quercetin results in increased phosphorylation of RPS6KA5 protein CTD PMID:18377872 quercetin multiple interactions ISO RGD:1318046 6480464 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Quercetin results in increased phosphorylation of RPS6KA5 protein] CTD PMID:18377872 Ro 31-8220 decreases activity EXP 6480464 Ro 31-8220 results in decreased activity of RPS6KA5 protein CTD PMID:15522277 SB 203580 multiple interactions ISO RGD:1318046 6480464 [U 0126 co-treated with SB 203580] inhibits the reaction [sodium arsenite results in increased activity of RPS6KA5 protein], SB 203580 inhibits the reaction [sodium arsenite results in increased activity of RPS6KA5 protein] CTD PMID:12547826 SB 203580 multiple interactions EXP 6480464 SB 203580 inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of RPS6KA5 protein] CTD PMID:15522277 SB 431542 multiple interactions ISO RGD:1318046 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPS6KA5 mRNA CTD PMID:27188386 SCH 23390 multiple interactions ISO RGD:1318047 6480464 SCH 23390 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of RPS6KA5 protein] CTD PMID:19187092 silicon dioxide increases expression ISO RGD:1318046 6480464 Silicon Dioxide analog results in increased expression of RPS6KA5 mRNA CTD PMID:25895662 silicon dioxide decreases expression ISO RGD:1318047 6480464 Silicon Dioxide results in decreased expression of RPS6KA5 mRNA CTD PMID:29203145 silver atom decreases expression ISO RGD:1318047 6480464 Silver results in decreased expression of RPS6KA5 mRNA CTD PMID:27131904 silver(0) decreases expression ISO RGD:1318047 6480464 Silver results in decreased expression of RPS6KA5 mRNA CTD PMID:27131904 SL-327 multiple interactions ISO RGD:1318047 6480464 SL 327 inhibits the reaction [[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of RPS6KA5 protein], SL 327 inhibits the reaction [Cocaine results in increased phosphorylation of and results in increased activity of RPS6KA5 protein] CTD PMID:16339038 , PMID:17596448 sodium arsenite multiple interactions ISO RGD:1318046 6480464 [U 0126 co-treated with SB 203580] inhibits the reaction [sodium arsenite results in increased activity of RPS6KA5 protein] more ... CTD PMID:12547826 sodium arsenite decreases expression ISO RGD:1318046 6480464 sodium arsenite results in decreased expression of RPS6KA5 mRNA CTD PMID:28595984 sodium arsenite increases activity ISO RGD:1318046 6480464 sodium arsenite results in increased activity of RPS6KA5 protein CTD PMID:12547826 succimer multiple interactions ISO RGD:1318047 6480464 [Succimer binds to Magnetite Nanoparticles] which results in decreased expression of RPS6KA5 mRNA CTD PMID:21641980 sunitinib increases expression ISO RGD:1318046 6480464 Sunitinib results in increased expression of RPS6KA5 mRNA CTD PMID:31533062 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of RPS6KA5 mRNA CTD PMID:25729387 topotecan decreases expression EXP 6480464 Topotecan results in decreased expression of RPS6KA5 mRNA CTD PMID:25729387 trichostatin A increases expression ISO RGD:1318046 6480464 trichostatin A results in increased expression of RPS6KA5 mRNA CTD PMID:24935251 , PMID:26272509 trichostatin A multiple interactions ISO RGD:1318046 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RPS6KA5 mRNA CTD PMID:27188386 urethane increases expression ISO RGD:1318046 6480464 Urethane results in increased expression of RPS6KA5 mRNA CTD PMID:28818685 valproic acid multiple interactions ISO RGD:1318046 6480464 [Hydralazine co-treated with Valproic Acid] results in increased expression of RPS6KA5 mRNA CTD PMID:17183730 valproic acid decreases methylation ISO RGD:1318046 6480464 Valproic Acid results in decreased methylation of RPS6KA5 gene CTD PMID:28853863 more ... valproic acid increases expression ISO RGD:1318046 6480464 Valproic Acid results in increased expression of RPS6KA5 mRNA CTD PMID:29154799 valproic acid decreases expression ISO RGD:1318046 6480464 Valproic Acid results in decreased expression of RPS6KA5 mRNA CTD PMID:23179753 , PMID:28001369 vinclozolin decreases expression EXP 6480464 vinclozolin results in decreased expression of RPS6KA5 mRNA CTD PMID:18042343 vinclozolin affects expression EXP 6480464 vinclozolin affects the expression of RPS6KA5 mRNA CTD PMID:19015723 Y-27632 decreases activity ISO RGD:1318046 6480464 Y 27632 results in decreased activity of RPS6KA5 protein CTD PMID:10998351
Biological Process histone H2A-S1 phosphorylation ISO RGD:1318046 1624291 (PMID:15010469) RGD PMID:15010469 histone H3-S10 phosphorylation ISO RGD:1318046 1624291 (PMID:12773393) RGD PMID:12773393 histone H3-S28 phosphorylation ISO RGD:1318046 1624291 (PMID:12773393) RGD PMID:12773393 histone phosphorylation ISO RGD:1318046 1624291 (PMID:9873047) RGD PMID:9873047 interleukin-1-mediated signaling pathway ISO RGD:1318046 1624291 (PMID:20018936) RGD PMID:20018936 intracellular signal transduction ISO RGD:1318046 1624291 (PMID:9687510) RGD PMID:9687510 intracellular signal transduction ISO RGD:1318047 1624291 (MGI:3687920, PMID:12628924) RGD MGI:3687920 , PMID:12628924 negative regulation of transcription, DNA-templated ISO RGD:1318046 1624291 (PMID:15010469) RGD PMID:15010469 positive regulation of histone acetylation ISO RGD:1318046 1624291 (PMID:20018936) RGD PMID:20018936 positive regulation of histone phosphorylation ISO RGD:1318046 1624291 (PMID:20018936) RGD PMID:20018936 positive regulation of NF-kappaB transcription factor activity ISO RGD:1318046 1624291 (PMID:12628924), (PMID:18511904) RGD PMID:12628924 , PMID:18511904 positive regulation of transcription by RNA polymerase II ISO RGD:1318046 1624291 (PMID:20018936) RGD PMID:20018936 protein phosphorylation ISO RGD:1318046 1624291 (PMID:9687510) RGD PMID:9687510 protein phosphorylation ISO RGD:1318047 1624291 (MGI:3687920, PMID:12628924) RGD MGI:3687920 , PMID:12628924 regulation of transcription, DNA-templated ISO RGD:1318046 1624291 (PMID:12763138), (PMID:9687510) RGD PMID:12763138 , PMID:9687510 regulation of transcription, DNA-templated ISO RGD:1318047 1624291 (MGI:3687920, PMID:12628924) RGD MGI:3687920 , PMID:12628924 Cellular Component cytoplasm ISO RGD:1318046 1624291 (PMID:18511904) RGD PMID:18511904 nucleoplasm ISO RGD:1318046 1624291 RGD GO_REF:0000052 nucleoplasm IEA UniProtKB:O75582 , ensembl:ENSP000004796671600115 GO_REF:0000107 Ensembl GO_REF:0000107 nucleus ISO RGD:1318046 1624291 (PMID:12628924), (PMID:18511904), (PMID:9687510) RGD PMID:12628924 more ... nucleus ISO RGD:1318047 1624291 (MGI:3687920, PMID:12628924) RGD MGI:3687920 , PMID:12628924 ribosome IEA UniProtKB-KW:KW-0689 1600115 GO_REF:0000043 UniProt GO_REF:0000043 Molecular Function ATP binding ISO RGD:1318046 1624291 (PMID:9687510) RGD PMID:9687510 ATP binding ISO RGD:1318047 1624291 (MGI:3687920, PMID:12628924) RGD MGI:3687920 , PMID:12628924 magnesium ion binding IEA InterPro:IPR016239 1600115 GO_REF:0000002 InterPro GO_REF:0000002 protein binding ISO RGD:1318046 1624291 UniProtKB:Q04206 more ... RGD PMID:12628924 more ... protein binding ISO RGD:1318047 1624291 UniProtKB:P11416 (MGI:3830444 , PMID:19078967) RGD MGI:3830444 , PMID:19078967 protein kinase activity ISO RGD:1318046 1624291 (PMID:9873047) RGD PMID:9873047 protein serine kinase activity IEA EC:2.7.11.1 1600115 GO_REF:0000003 UniProt GO_REF:0000003 protein serine/threonine kinase activity ISO RGD:1318046 1624291 (PMID:12773393), (PMID:9687510) RGD PMID:12773393 , PMID:9687510 protein serine/threonine kinase activity ISO RGD:1318047 1624291 (MGI:3687920, PMID:12628924) RGD MGI:3687920 , PMID:12628924 protein threonine kinase activity IEA EC:2.7.11.1 1600115 GO_REF:0000003 UniProt GO_REF:0000003
Gene-Chemical Interaction Annotations
